Bayer, the German chemical and drug giant that makes aspirin and Alka-Seltzer, said on Monday that it would buy the over-the-counter (OTC) drug business of the Swiss pharmaceuticals company Roche in a deal worth about US$2.95 billion that would create a world leader in non-prescription medicines.
If the deal is approved by antitrust officials in Europe and the US, the enlarged Bayer consumer health care unit would continue to be based in Morristown, New Jersey, and be led by Gary Balkema, the president of Bayer Healthcare. The combined operations would have 6,700 employees in 120 countries.
Roche, whose main OTC products, like Rennie antacid and Supradyn vitamins, are known mainly outside the US, had put the non-prescription business on the market in order to focus on its pharmaceuticals and medial diagnostics business.
Its leading prescription drugs include Pegsys and Copegus, sold as a combination treatment for hepatitis C, Fuzeon, an AIDS drug, and Herceptin, for breast cancer.
For Bayer, whose pharmaceuticals business has stumbled, the move gives the company more clout in over-the-counter treatments and greater geographical balance in that business, which Bayer executives expect to reach 2.4 billion euros (SU$2.98 billion) after the merger.
In consumer health products, including nutritional products and vitamins, the bigger Bayer would rank behind Johnson & Johnson, GlaxoSmithKline, Procter & Gamble and Novartis. But in OTC alone, it would be third, after Johnson & Johnson and GlaxoSmithKline.
"It is our stated goal to expand our OTC business further and to become the No. 1 worldwide," Bayer's chief executive, Werner Wenning, said in a statement. "With the acquisition, we have taken a big step closer towards our goal."
Investors, though, indicated doubts about Bayer's strategy and its ability to finance the deal, which is to be paid for at least in part from the company's cash flow.
Standard & Poor's lowered Bayer's long-term debt to A from A+, on questions about the deal's affect on the company's ability to meet debt obligations.
Moody's Investors Service, however, affirmed its A3 rating for Bayer, citing the deal's ability to strengthen the company's position in consumer healthcare, a business with high profit margins.
Analysts said the transaction could help counter possible negative effects from Bayer's plans to spin off its Lanxess chemicals unit, which represents about 20 percent of the company's sales.
The deal also reduces emphasis on Bayer's pharmaceuticals business, which has had trouble with developing new drugs. Its leading antibiotic, Ciprol, has been losing market share to generic drugs.
And it is still grappling with thousands of lawsuits by people who said they suffered side effects from Bayer's cholesterol treatment, Baycol, which the company withdrew from the market in 2001.
Bayer said that the acquisition would incur one-time charges of some 300 million euros and reduce earnings per share by 0.25 euros next year, but that it expected a positive effect on results in 2006 and cost savings of 100 million euros to 120 million euros over the next three years.
Under the deal, Bayer will buy out Roche's half of the companies' joint venture in the US, which include marketing the nonprescription painkiller Alleve.
One of two tropical depressions that formed off Taiwan yesterday morning could turn into a moderate typhoon by the weekend, the Central Weather Administration (CWA) said yesterday. Tropical Depression No. 21 formed at 8am about 1,850km off the southeast coast, CWA forecaster Lee Meng-hsuan (李孟軒) said. The weather system is expected to move northwest as it builds momentum, possibly intensifying this weekend into a typhoon, which would be called Mitag, Lee said. The radius of the storm is expected to reach almost 200km, she said. It is forecast to approach the southeast of Taiwan on Monday next week and pass through the Bashi Channel
The number of Chinese spouses applying for dependent residency as well as long-term residency in Taiwan has decreased, the Mainland Affairs Council said yesterday, adding that the reduction of Chinese spouses staying or living in Taiwan is only one facet reflecting the general decrease in the number of people willing to get married in Taiwan. The number of Chinese spouses applying for dependent residency last year was 7,123, down by 2,931, or 29.15 percent, from the previous year. The same census showed that the number of Chinese spouses applying for long-term residency and receiving approval last year stood at 2,973, down 1,520,
EASING ANXIETY: The new guide includes a section encouraging people to discuss the threat of war with their children and teach them how to recognize disinformation The Ministry of National Defense’s All-Out Defense Mobilization Agency yesterday released its updated civil defense handbook, which defines the types of potential military aggression by an “enemy state” and self-protection tips in such scenarios. The agency has released three editions of the handbook since 2022, covering information from the preparation of go-bags to survival tips during natural disasters and war. Compared with the previous edition, released in 2023, the latest version has a clearer focus on wartime scenarios. It includes a section outlining six types of potential military threats Taiwan could face, including destruction of critical infrastructure and most undersea cables, resulting in
The Central Weather Administration (CWA) yesterday said that it expected to issue a sea warning for Typhoon Ragasa this morning and a land warning at night as it approached Taiwan. Ragasa intensified from a tropical storm into a typhoon at 8am yesterday, the CWA said, adding that at 2pm, it was about 1,110km east-southeast of Oluanpi (鵝鑾鼻), Taiwan’s southernmost tip. The typhoon was moving northwest at 13kph, with sustained winds of up to 119kph and gusts reaching 155kph, the CWA Web site showed. Forecaster Liu Pei-teng (劉沛滕) said that Ragasa was projected to strengthen as it neared the Bashi Channel, with its 200km
RSS